The mRNA vaccines that were made during the COVID-19 pandemic used processes that were a brute force scaleup of lab processes, according to Alexei Voloshin,...
In health care crises, researchers can avoid waiting for clinical trial results by using data from health care systems to analyze the effectiveness of...
Synthetic drugs that emulate natural agents can overcome challenges such as biocompatibility, adverse reactions, toxicity, and long-term efficacy. The...
PITTSBURGH, April 3, 2023 – The COVID-19 pandemic created a real-life experiment that demanded health care providers nationwide rapidly stand up clinics...
LA JOLLA, CA—A team of scientists from Scripps Research and the University of North Carolina (UNC) has found antibodies in the blood of certain COVID-19...
Viruses, including SARS-CoV-2, use an extensive arsenal to help them cleverly evade the immune system, proliferate and cause disease. Among their formidable...
A new class of SARS-CoV-2 antibodies has been shown to neutralise multiple variants of the virus, providing hope for a better antiviral medication to prevent...
It is becoming increasingly clear that we have misunderstood SARS-CoV-2, the virus that causes COVID-19. Many people, including some experts in the scientific...
2023 has been surprising for most market participants. Sentiment was in the toilet to close out 2022. And the first two weeks of this year […]...
Some things that come in threes are seen in a positive light. But threes also have their dark side, as evidenced by the so-called tripledemic—the unprecedented...
Coldspot-guided antibody discovery (a screening approach that focuses on portions of the SARS-CoV-2 spike glycoprotein that are both functionally relevant...
The XBB.1.5 subvariant — nicknamed ‘Kraken’ — is arguably the most genetically rich and most transmissible SARS-CoV-2 Omicron subvariant yet.
Editor-in-chief Jonah Comstock lays out a few of the most potent threads he heard in the conference centres, The post JPM2023: Breakthroughs await, but...
FDA Approves Monoclonal Antibody To Treat COVID-19 For First Time Authored by Mimi Nguyen Ly via The Epoch Times (emphasis ours), The U.S....
A review of the latest executive moves in the pharma industry over the past several months.
With the Biotechnology space rotating toward a more acquisition friendly dynamic, investors may benefit from a studied focus on likely takeout candidates...
Following an invite to fly into Parma, Italy to witness first-hand the press launch of the considerable structure The post Touring Chiesi’s vision for...
Are the currently approved antibody therapies used to treat individuals at increased risk for severe COVID-19 disease also effective against currently...
To create the best cold chain for a therapy, bioprocessors need to plan ahead. Product challenges directly impact biologics, and that’s the focus when...
Nascent Biotech Inc. (OTCMKTS:NBIO) is an emerging player in the $4 billion oncology drug development space. NBIO is early-stage – its flagship drug...
Christian Olsen, PhD, business segment lead at Dotmatics, discusses the balancing act needed to succeed at the fulcrum of the incredible potential that...
A monoclonal antibody against heroin (11D12) is effective in blocking the euphoric and lethal effects of this much-abused opioid. The current findings...
The Galien Foundation, which acknowledges “extraordinary scientific innovations that improve the human condition”, has awarded its Best Biotechnology The...
Nascent Biotech Inc. (OTCMKTS:NBIO) is an interesting name in the oncology treatment space. The company is in the very final phases of its first phase...
With COVID-19 on the scene, talk of other respiratory viruses has taken a backseat. But this doesn’t change the fact that they are as present as...
A study at Karolinska Institutet in Sweden shows that the coronavirus variant BA.2.75.2, an Omicron sublineage, largely evades neutralizing antibodies...
Targeted business development acquisitions, improvements in R&D and operating performance, and a strengthened post-demerger balance sheet are creating...
A strong product pipeline and increased group sales confirm that Roche is on the right growth path.
In the Phase II VISIONARY-MS trial (NCT03536559), which evaluated CNM-Au8 in participants with stable relapsing remitting multiple sclerosis (RRMS), CNM-Au8...
Antiretroviral therapies for HIV, while extremely effective, need to be taken daily for life. Designing antibody treatments that need to be taken only...